VRDN Viridian Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRDN

Price (delayed)

$16.575

Market cap

$1.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.34

Enterprise value

$1.62B

?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 12
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 29

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal ...

Highlights
VRDN's quick ratio is down by 22% year-on-year but it is up by 19% since the previous quarter
The equity fell by 12% QoQ but it rose by 5% YoY
The net income has contracted by 17% YoY and by 5% from the previous quarter
Viridian Therapeutics's debt has increased by 2.8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.viridiantherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VRDN

VRDN stock price

How has the Viridian Therapeutics stock price performed over time
Intraday
1.38%
1 week
-5.01%
1 month
17.89%
1 year
17.14%
YTD
-46.74%
QTD
-15.26%

Financial performance

How have Viridian Therapeutics's revenue and profit performed over time
Revenue
$70.92M
Gross profit
$70.92M
Operating income
-$385.7M
Net income
-$360.59M
Gross margin
100%
Net margin
-508.5%
The operating margin has soared by 100% YoY but it has decreased by 6% QoQ
Viridian Therapeutics's net margin has surged by 100% YoY but it has decreased by 5% QoQ
The net income has contracted by 17% YoY and by 5% from the previous quarter
The operating income has declined by 14% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does VRDN's price correlate with its fundamentals

Growth

What is Viridian Therapeutics's growth rate over time

Valuation

What is Viridian Therapeutics stock price valuation
P/E
N/A
P/B
2.66
P/S
23.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.82
The price to book (P/B) is 18% less than the last 4 quarters average of 3.2 but 10% more than the 5-year quarterly average of 2.4
The equity fell by 12% QoQ but it rose by 5% YoY
The P/S is 99% less than the 5-year quarterly average of 1574.8 and 98% less than the last 4 quarters average of 957.6

Efficiency

How efficient is Viridian Therapeutics business performance
Viridian Therapeutics's return on sales has surged by 100% YoY but it has decreased by 4.4% QoQ
The company's return on equity fell by 24% YoY and by 3.9% QoQ
Viridian Therapeutics's return on invested capital has decreased by 15% YoY
The return on assets has declined by 13% year-on-year

Dividends

What is VRDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRDN.

Financial health

How did Viridian Therapeutics financials performed over time
The total liabilities has soared by 171% YoY but it has decreased by 14% QoQ
VRDN's quick ratio is down by 22% year-on-year but it is up by 19% since the previous quarter
Viridian Therapeutics's debt is 86% lower than its equity
The debt to equity has grown by 17% from the previous quarter
The equity fell by 12% QoQ but it rose by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.